Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
32.73
+1.04 (3.28%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.64 - 32.79
52 week 27.92 - 45.45
Open 31.64
Vol / Avg. 1.07M/650,742.00
Mkt cap 1.36B
P/E 136.71
Div/yield     -
EPS 0.24
Shares 42.85M
Beta 1.14
Inst. own 108%
Oct 28, 2015
Q3 2015 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 9, 2015
Acorda Therapeutics Inc at Robert W Baird and Co Health Care Conference - 2:00PM EDT - Add to calendar
Aug 12, 2015
Acorda Therapeutics Inc at Canaccord Genuity Growth Conference
Jul 30, 2015
Q2 2015 Acorda Therapeutics Inc Earnings Release
Jul 30, 2015
Q2 2015 Acorda Therapeutics Inc Earnings Call
Jun 9, 2015
Acorda Therapeutics Inc Annual Shareholders Meeting
Jun 5, 2015
Acorda Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 2, 2015
Acorda Therapeutics Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 0.88% 4.40%
Operating margin 5.01% 9.06%
EBITD margin - 12.92%
Return on average assets 0.36% 2.09%
Return on average equity 0.72% 3.60%
Employees 489 -
CDP Score - -

Address

420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Company’s markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinson’s disease, epilepsy, heart failure, MS, and spinal cord injury.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael W Rogers Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 42
Bio & Compensation  - Reuters
David W Lawrence Chief - Business Operations
Age: 57
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 51
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters